Clinical trial programs (SURPASS in T2D, SURMOUNT in obesity) have consistently demonstrated that tirzepatide induces much more pronounced weight loss than placebo and has superior efficacy compared to selective GLP-1 RAs like semaglutide (1 mg dose). Here, GLP1R is linked to obesity disorder.